TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 11/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-4.31%-6.62%+65.79%+98.02% 69.06B
+1.16%+0.48%+48.17%+86.32% 63.06B
-3.22%+23.17%+1.75%-5.23% 28.34B
-1.42%-3.38%-5.99%+465.34% 27.07B
+7.41%+7.45%+56.85%+17.70% 25.45B
+2.25%+2.61%+37.12%-16.09% 19.69B
+5.36%+4.61%+270.18%+415.10% 19.19B
+0.10%-3.50%+11.43%+519.16% 15.95B
+0.87%+4.26%+41.21%+150.80% 13.52B
Average +1.26%+3.27%+58.50%+192.35% 31.26B
Weighted average by Cap. +0.43%+1.66%+55.35%+153.14%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock